PT-141 (Bremelanotide)
Melanocortin-4 receptor agonist · approved for HSDD
Overview
PT-141 (Bremelanotide) is a melanocortin-4 receptor agonist approved in the US (Vyleesi) for premenopausal HSDD. Studied in sexual-function and neuroendocrine research.
Specifications
- CAS
- 189691-06-3
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 10 mg
- MOQ
- On request
- Lead time
- 10–18 days
- Storage
- -20°C, protect from light
Documentation available on request
- Certificate of Analysis (COA)
- HPLC Chromatogram
- Mass-spec spectrum
- Stability data
- SDS / MSDS
- Sequence verification
Regulatory note
Heavily regulated; approved as a prescription drug in some jurisdictions. Sold only to qualified buyers with appropriate licensing in their jurisdiction. Order requires compliance review.
Related peptides